Investor Presentaiton
Novo Nordisk Annual Report 2023
Financial statements of the parent company
8 Financial assets
Amounts owed Investment in
Other
DKK million
Cost at the beginning of the year
Investments during the year
Investments in
subsidiaries
by affiliated
companies
associated
company
securities and
investments
2023
2022
9 Other receivables and prepayments
Other receivables and prepayments includes prepayments of DKK 5,375 million,
primarily related to prepaid contract manufacturing and R&D activities
54,660
4,975
105
757
60,497
53,987
10 Share capital
5,170
800
124
6,094
6,697
Divestments and repayments during the year
(29)
(3,328)
(63)
(3,420)
(187)
For information on share capital, refer to note 4.3 to the consolidated financial
statements.
Cost at the end of the year
59,801
2,447
105
818
63,171
60,497
Value adjustments at the beginning of the year
34,407
292
90
(268)
34,521
35,933
11 Derivatives
Profit/(loss) before tax
18,112
18,112
19,713
Share of result after tax in associated company
(38)
(38)
(4)
Income taxes on profit for the year
(1,332)
(1,332)
(1,596)
For information on derivative financial instruments, refer to note 4.5 to the consolidat-
ed financial statements. All derivatives in the group are entered into with Novo Nordisk
A/S as the counterpart.
Market value adjustment
Dividends received
(6)
(6)
Divestments during the year
Effect of exchange rate adjustment charged to the income statement
Effect of exchange rate adjustment charged to equity
Other adjustments
Value adjustments at the end of the year
Unrealised internal profit at the beginning of the year
Unrealised internal profit movements in the year
Effect of exchange rate adjustment charged to equity
Unrealised internal profit at the end of the year
(9,127)
29
(271)
(2,285)
1,467
41,271
21
(9,127)
(135)
(23,305)
12 Borrowings
25
25
54
DKK million
(96)
(367)
220
Within 1 year
(2,285)
1,768
1-5 years
1,467
1,927
More than 5 years
62
52
(345)
40,999
34,521
Total borrowings
2023
2022
5,072
169
12,889
12,627
3,966
8,572
21,927
21,368
(16,712)
(16,712)
(18,356)
Borrowings mainly consist of loans from Novo Nordisk Finance (Netherlands) B.V.
(807)
892
(16,627)
84,445
(807)
1,121
related to issuance of Eurobonds.
892
523
(16,627)
(16,712)
2,468
157
473
87,543
78,306
Carrying amount at the end of the year
For a list of companies in the Novo Nordisk Group, refer to note 5.7 to the consolidated financial statements.
110View entire presentation